TokenPost·
Latigo Biotherapeutics’ Q3 Loss Per Share Beats Estimate by $0.12
The company expects $401 million in cash and cash equivalents to fund operations into 2029.
More news
- CryptoSlateMEXC sees $126 million outflows as US targets exchange over $16.7 billion in suspected illicit transactions
- TokenPostZiff Davis’ Operating Results Swing to Loss as Revenue Falls 5.6%
- TokenPostTokenized iShares MSCI South Korea ETF (EWY) Falls 1.22% as Price Sits Below Averages
- TokenPostJim Cramer Says AI Stock Sell-Off Differs From Dot-Com Crash
- TokenPostMichael Saylor Says Bitcoin (BTC) Fell About 5% in Nov. 5 Post
- TokenPostXponential Fitness Cuts 2026 Studio Target as Revenue Falls 21%